Cargando…

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study

BACKGROUND: Neutropenia is a common toxicity in patients receiving myelosuppressive chemotherapy. In this prospective pilot study, we compared the efficacy and safety profiles of pegfilgrastim administered subcutaneously once per cycle and lenograstim administered subcutaneously daily six times per...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Luigi, Tomao, Federica, Lo Russo, Giuseppe, Papa, Anselmo, Zoratto, Federica, Marzano, Raffaella, Basso, Enrico, Giordani, Erika, Verrico, Monica, Ricci, Fabio, Pasciuti, Giulia, Francini, Edoardo, Tomao, Silverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832460/
https://www.ncbi.nlm.nih.gov/pubmed/24255599
http://dx.doi.org/10.2147/TCRM.S48387
_version_ 1782291684007084032
author Rossi, Luigi
Tomao, Federica
Lo Russo, Giuseppe
Papa, Anselmo
Zoratto, Federica
Marzano, Raffaella
Basso, Enrico
Giordani, Erika
Verrico, Monica
Ricci, Fabio
Pasciuti, Giulia
Francini, Edoardo
Tomao, Silverio
author_facet Rossi, Luigi
Tomao, Federica
Lo Russo, Giuseppe
Papa, Anselmo
Zoratto, Federica
Marzano, Raffaella
Basso, Enrico
Giordani, Erika
Verrico, Monica
Ricci, Fabio
Pasciuti, Giulia
Francini, Edoardo
Tomao, Silverio
author_sort Rossi, Luigi
collection PubMed
description BACKGROUND: Neutropenia is a common toxicity in patients receiving myelosuppressive chemotherapy. In this prospective pilot study, we compared the efficacy and safety profiles of pegfilgrastim administered subcutaneously once per cycle and lenograstim administered subcutaneously daily six times per cycle, for primary neutropenia prophylaxis in women with breast cancer receiving adjuvant anthracycline-based chemotherapy. MATERIALS AND METHODS: Twenty women were enrolled. All patients received epirubicin 100 mg/m(2) with 5-fluorouracil 500 mg/m(2) and cyclophosphamide 500 mg/m(2) on day 1 and every 21 days thereafter, according to the FEC 100 chemotherapy regimen. Eight patients received a single dose of pegfilgrastim on day 2, while 12 patients were treated with daily administration of lenograstim from days five to ten. Absolute neutrophil count and duration of grade 3–4 neutropenia were monitored using seriated blood samples. The incidence of bone pain was evaluated using the visual analog scale (VAS). RESULTS: The incidence of grade 3–4 neutropenia was 75% in patients who received pegfilgrastim, and 25% in patients who received lenograstim. One case of febrile neutropenia was shown in pegfilgrastim patients. The mean duration of grade 3–4 neutropenia was 2 days in pegfilgrastim group versus 1.4 days in the lenograstim group. Bone pain was present in 37.5% of pegfilgrastim patients versus 58.3% of lenograstim patients. The mean duration of bone pain in the pegfilgrastim group was 4 days versus 6 days in the lenograstim group. CONCLUSION: In our experience, a single injection of pegfilgrastim was less effective for controlling neutropenia than six daily injections of lenograstim. The safety profiles of pegfilgrastim and lenograstim were similar with a lower incidence of bone pain in patients treated with pegfilgrastim.
format Online
Article
Text
id pubmed-3832460
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38324602013-11-19 Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study Rossi, Luigi Tomao, Federica Lo Russo, Giuseppe Papa, Anselmo Zoratto, Federica Marzano, Raffaella Basso, Enrico Giordani, Erika Verrico, Monica Ricci, Fabio Pasciuti, Giulia Francini, Edoardo Tomao, Silverio Ther Clin Risk Manag Original Research BACKGROUND: Neutropenia is a common toxicity in patients receiving myelosuppressive chemotherapy. In this prospective pilot study, we compared the efficacy and safety profiles of pegfilgrastim administered subcutaneously once per cycle and lenograstim administered subcutaneously daily six times per cycle, for primary neutropenia prophylaxis in women with breast cancer receiving adjuvant anthracycline-based chemotherapy. MATERIALS AND METHODS: Twenty women were enrolled. All patients received epirubicin 100 mg/m(2) with 5-fluorouracil 500 mg/m(2) and cyclophosphamide 500 mg/m(2) on day 1 and every 21 days thereafter, according to the FEC 100 chemotherapy regimen. Eight patients received a single dose of pegfilgrastim on day 2, while 12 patients were treated with daily administration of lenograstim from days five to ten. Absolute neutrophil count and duration of grade 3–4 neutropenia were monitored using seriated blood samples. The incidence of bone pain was evaluated using the visual analog scale (VAS). RESULTS: The incidence of grade 3–4 neutropenia was 75% in patients who received pegfilgrastim, and 25% in patients who received lenograstim. One case of febrile neutropenia was shown in pegfilgrastim patients. The mean duration of grade 3–4 neutropenia was 2 days in pegfilgrastim group versus 1.4 days in the lenograstim group. Bone pain was present in 37.5% of pegfilgrastim patients versus 58.3% of lenograstim patients. The mean duration of bone pain in the pegfilgrastim group was 4 days versus 6 days in the lenograstim group. CONCLUSION: In our experience, a single injection of pegfilgrastim was less effective for controlling neutropenia than six daily injections of lenograstim. The safety profiles of pegfilgrastim and lenograstim were similar with a lower incidence of bone pain in patients treated with pegfilgrastim. Dove Medical Press 2013 2013-11-11 /pmc/articles/PMC3832460/ /pubmed/24255599 http://dx.doi.org/10.2147/TCRM.S48387 Text en © 2013 Rossi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Rossi, Luigi
Tomao, Federica
Lo Russo, Giuseppe
Papa, Anselmo
Zoratto, Federica
Marzano, Raffaella
Basso, Enrico
Giordani, Erika
Verrico, Monica
Ricci, Fabio
Pasciuti, Giulia
Francini, Edoardo
Tomao, Silverio
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
title Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
title_full Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
title_fullStr Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
title_full_unstemmed Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
title_short Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
title_sort efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy fec 100: a pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832460/
https://www.ncbi.nlm.nih.gov/pubmed/24255599
http://dx.doi.org/10.2147/TCRM.S48387
work_keys_str_mv AT rossiluigi efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT tomaofederica efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT lorussogiuseppe efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT papaanselmo efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT zorattofederica efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT marzanoraffaella efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT bassoenrico efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT giordanierika efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT verricomonica efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT riccifabio efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT pasciutigiulia efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT franciniedoardo efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy
AT tomaosilverio efficacyandsafetyanalysisofoncepercyclepegfilgrastimanddailylenograstiminpatientswithbreastcancerreceivingadjuvantmyelosuppressivechemotherapyfec100apilotstudy